GHRS Stock Forecast 2025-2026
Distance to GHRS Price Targets
GHRS Price Momentum
10 Quality Stocks Worth Considering Now
Researching GH Research (GHRS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GHRS and similar high-potential opportunities.
Latest GHRS Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, GHRS has a bullish consensus with a median price target of $33.50 (ranging from $31.00 to $40.00). Currently trading at $9.10, the median forecast implies a 268.1% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 339.6% upside. Conversely, the most conservative target is provided by Brian Abrahams at RBC Capital, suggesting a 240.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GHRS Analyst Ratings
GHRS Price Target Range
Latest GHRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GHRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Guggenheim | Eddie Hickman | Buy | Initiates | $32.00 |
| Mar 7, 2025 | RBC Capital | Brian Abrahams | Outperform | Initiates | $31.00 |
| Feb 27, 2025 | Stifel | Paul Matteis | Buy | Maintains | $32.00 |
| Feb 13, 2025 | Cantor Fitzgerald | Charles Duncan | Overweight | Initiates | $14.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Nov 18, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $28.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Sep 4, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $39.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| May 7, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| May 6, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $31.00 |
| Mar 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Mar 1, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $39.00 |
| Jan 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Dec 18, 2023 | Stifel | Buy | Maintains | $0.00 | |
| Nov 14, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $40.00 |
| Jul 6, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
GH Research plc (GHRS) Competitors
The following stocks are similar to GH Research based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GH Research plc (GHRS) Financial Data
GH Research plc has a market capitalization of $564.46M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -19.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
GH Research plc (GHRS) Business Model
About GH Research plc
Develops therapies for mental health conditions.
The company focuses on creating innovative therapeutics for treatment-resistant depression, primarily using psychedelic compounds. By leveraging novel drug development technologies, GH Research plc aims to provide solutions that traditional antidepressants cannot, tapping into the growing market for effective mental health treatments.
Based in Dublin, GH Research plc is positioned in a rapidly expanding niche within the biotechnology industry. The increasing global demand for effective mental health solutions, coupled with the scientific validation of psychedelic therapies, enhances its appeal to investors looking for opportunities at the forefront of healthcare innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
50
CEO
Dr. Theis Terwey M.D.
Country
Ireland
IPO Year
2021
Website
www.ghres.comGH Research plc (GHRS) Latest News & Analysis
GH Research PLC is conducting a Phase 2b trial for GH001 in treatment-resistant depression, aiming to complete by Q1 2025. They reported $182.6M in assets as of Dec 2024 and secured $139.8M from a Feb 2025 offering.
The progress of GH001 in clinical trials and substantial cash reserves indicate strong potential for future growth, making GH Research PLC a compelling investment opportunity in the biopharmaceutical sector.
GH Research PLC (Nasdaq: GHRS) has priced a public offering of 10 million shares at $15 each, raising approximately $150 million. The offering closes on February 6, 2025, with an option for underwriters to buy 1.5 million more shares.
GH Research's $150 million public offering indicates strong capital raising efforts, which could fund further development of its depression treatment, influencing investor confidence and stock performance.
GH Research stock increased 55% over the week following positive results from a mid-stage depression study for its lead candidate, GH001.
GH Research's 55% stock surge indicates strong investor confidence following positive trial results for GH001, signaling potential revenue growth and market approval.
Why Is GH Research Stock Trading Higher On Monday?
2 months agoGH Research PLC (GHRS) announced that its Phase 2b trial for GH001, an inhalable treatment for resistant depression, successfully met its primary endpoint.
GH Research's successful Phase 2b trial for GH001 indicates potential market approval, enhancing growth prospects and investor confidence in the company's future value.
GH Research PLC (Nasdaq: GHRS) announced successful results from a Phase 2b trial of GH001 for treatment-resistant depression. A conference call is scheduled for today at 8 a.m. EST.
GH Research's successful Phase 2b trial results for GH001 in treatment-resistant depression could enhance its market position and attract investment, reflecting potential future revenue growth.
GH Research Announces Proposed Public Offering
2 months agoGH Research PLC (Nasdaq: GHRS) has launched a $150 million underwritten public offering of ordinary shares, with an option for underwriters to purchase an additional $22.5 million.
GH Research's $150 million public offering signals potential dilution of shares, impacting stock valuation. Market conditions will influence its success, affecting investor sentiment and future funding.
Frequently Asked Questions About GHRS Stock
What is GH Research plc's (GHRS) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, GH Research plc (GHRS) has a median price target of $33.50. The highest price target is $40.00 and the lowest is $31.00.
Is GHRS stock a good investment in 2025?
According to current analyst ratings, GHRS has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GHRS stock?
Wall Street analysts predict GHRS stock could reach $33.50 in the next 12 months. This represents a 268.1% increase from the current price of $9.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GH Research plc's business model?
The company focuses on creating innovative therapeutics for treatment-resistant depression, primarily using psychedelic compounds. By leveraging novel drug development technologies, GH Research plc aims to provide solutions that traditional antidepressants cannot, tapping into the growing market for effective mental health treatments.
What is the highest forecasted price for GHRS GH Research plc?
The highest price target for GHRS is $40.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 339.6% increase from the current price of $9.10.
What is the lowest forecasted price for GHRS GH Research plc?
The lowest price target for GHRS is $31.00 from Brian Abrahams at RBC Capital, which represents a 240.7% increase from the current price of $9.10.
What is the overall GHRS consensus from analysts for GH Research plc?
The overall analyst consensus for GHRS is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $33.50.
How accurate are GHRS stock price projections?
Stock price projections, including those for GH Research plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.